Trials / Recruiting
RecruitingNCT06797336
A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
A Phase 1, Open-Label Dose Escalation and Expansion Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 115 (estimated)
- Sponsor
- PAQ Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0253 in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutated advanced solid tumors as monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PT0253 | PT0253 injection. |
Timeline
- Start date
- 2024-12-19
- Primary completion
- 2026-12-15
- Completion
- 2027-06-16
- First posted
- 2025-01-28
- Last updated
- 2025-12-18
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06797336. Inclusion in this directory is not an endorsement.